Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA

Next Previous
Trial Profile

Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ORIENT
  • Sponsors AbbVie

Most Recent Events

  • 17 Feb 2016 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020 as reported by ClinicalTrials.gov record.
  • 17 Feb 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Feb 2020 as reported by ClinicalTrials.gov record.
  • 17 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top